Navigation Links
Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry
Date:6/3/2009

- Improvement Was Noted At Day 3 And All Subsequent Study Visits -

FORT LEE, N.J., June 3 /PRNewswire/ -- Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today that positive results from a phase 2 clinical trial for lurasidone in the treatment of patients with schizophrenia have been published in The Journal of Clinical Psychiatry. This six-week, randomized, double-blind, multicenter, placebo-controlled trial, involving 180 patients with acute schizophrenia, evaluated a single fixed dose of lurasidone 80 mg/day versus placebo. Lurasidone 80 mg/day produced statistically significant improvement versus placebo in both primary and secondary efficacy assessments at all study visits starting at day 3. In addition, lurasidone was generally well-tolerated and was associated with weight and metabolic changes that were similar to placebo. The study is available at www.psychiatrist.com.

"We are pleased to see the first publication reporting results of a lurasidone placebo-controlled trial in the treatment of patients with acute schizophrenia," said Antony Loebel, M.D., senior author and vice president of clinical research, Dainippon Sumitomo Pharma America, Inc. "Findings from this phase 2 study are consistent with data emerging from the lurasidone global development program, including a recently completed, large phase 3 placebo-controlled trial."

The primary efficacy measure was the BPRSd (Brief Psychiatric Rating Scale-derived). Lurasidone demonstrated significant improvement at Week 6 (LOCF endpoint) compared to placebo on the BPRSd (-8.9 vs. -4.2; p=0.012), as well as on all secondary efficacy measures, including the PANSS (Positive and Negative Syndrome Scale) total score (-14.1 vs. -5.5; p=0.004), PANSS positive subscale (-4.3 vs. -1.7; p=0.006), PANSS negative subscale (-2.9 vs. -1.3; p=0.025) and CGI-S (Clinical Global Impressions-Se
'/>"/>

SOURCE Dainippon Sumitomo Pharma Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. IMPACT Study Showed Longer Valcyte(R) (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant
2. Data From Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. Results and Additional Analyses From Study Show That Cortheras Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Study Showed Lillys GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients
9. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer
11. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... LUTHERVILLE, Md. , Aug. 20, 2014 /PRNewswire/ ... today lauded the latest results achieved by the ... known as the National Precursor Log Exchange (NPLEx), ... enforcement officials track down methamphetamine offenders and make ... in Missouri blocked the ...
(Date:8/20/2014)... SOUTH PLAINFIELD, N.J. , Aug. 20, 2014 PTC ... it will participate at two upcoming investor conferences: ... Four Seasons Hotel in Boston on ... Annual Biotech Conference at The Mandarin Oriental Boston on Thursday, ... will present a company update at the Bank of America ...
(Date:8/20/2014)... 2014 Reportlinker.com announces that a new ... The Impact of Healthcare Reform (PPACA) ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html The "Patient Protection ... legislation that affects virtually every aspect of health ... to take effect now. IVD manufacturers who have ...
Breaking Medicine Technology:Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2PTC Therapeutics to Participate at Upcoming Investor Conferences 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6
(Date:8/20/2014)... (PRWEB) August 20, 2014 The Board ... Perkins Eastman is pleased to announce the ... services in China and the surrounding region. ... Richard Sprow AIA has relocated to the ... career in healthcare planning and design and to better ...
(Date:8/20/2014)... persistent and deadliest infectious diseases in the world, killing ... who study tuberculosis have long debated its origins. New ... Africa to seals and sea lions that brought the ... people there before Europeans landed on the continent. , ... Source of New World Human Tuberculosis," was published in ...
(Date:8/20/2014)... Sockeye salmon that sprint to spawning grounds through fast-moving ... University of British Columbia scientists. , When salmon encounter ... downstream of dams they must move upstream using ... to sprinting for humans. , "Days after sockeye passed ... dying only a short distance from their spawning grounds," ...
(Date:8/20/2014)... 2014 As concerns regarding the health ... ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgery continue to ... from New York are urging the U.S. Food & ... devices. In a letter dated August 19th, Sens. Kirsten ... agency to seriously consider the testimony given during the ...
(Date:8/20/2014)... Research from Columbia University Medical Center shows that ... growth and that blocking nerve signals using surgery or ... disease. The study was conducted by the laboratory of ... MD, PhD, in Norway and is published in today,s ... have long observed that human and mouse cancers contain ...
Breaking Medicine News(10 mins):Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... A visionary leader, Dr.,Maria Cristina Escobar Fritzsche ... contributions to the prevention and control of ... Pan American Sanitary Conference,proceedings today. The Abraham ... bestowed upon creative leaders whose commitment to,public ...
... LMAT ), a provider of peripheral vascular devices ... to launch a,direct sales force in Italy in January ... Italy through an,exclusive distribution agreement with Serom Medical Technologies ... rights on,January 25, 2008 in exchange for the payment ...
... - A cadre of private and public entities in ... National Adopting Changes to Improve Outcomes Now (ACTION) Campaign ... Campaign goals are to increase access to addiction treatment ... in treatment. , The campaign, launched during National ...
... APFC ), today announced that Chairman and Chief,Executive ... Operating,officer, Dr. Joseph Carleone, and Vice President and Chief ... the CIBC World Market,2nd Annual Industrials Conference, October 2-3, ... is available on the Company,s web site. About ...
... combined treatment with rapamycin and Gleevec might reverse the ... disease, according to the results of a new study ... of Hepatology, a journal published by John Wiley & ... Study of Liver Diseases (AASLD). The article is also ...
... This strategy beat out either therapy alone, researchers found ... combination of cognitive behavior therapy plus antidepressant drugs is ... thoughts and behavior in depressed teens, new research shows. ... October issue of the journal Archives of General ...
Cached Medicine News:Health News:Inter-American Leadership Award Bestowed Upon Chilean Chronic Disease Expert 2Health News:LeMaitre Vascular to Start Italian Sales Force 2Health News:LeMaitre Vascular to Start Italian Sales Force 3Health News:Leaders in addiction treatment announce national 'ACTION' campaign 2Health News:Combination therapy reverses effects of portal hypertension in rats 2Health News:Drug Plus Psychotherapy Best Treatment for Depressed Teens 2
Long handle occluders are approximately 9 inches long....
Long handle occluders are approximately 9 inches long....
Basic external reading model....
Manual Lensmeter....
Medicine Products: